SCHEDULE: Armistice Capital Discloses 9.99% Stake in Revelation Biosciences

Armistice Capital, LLC and Steven Boyd have reported a 9.99% beneficial ownership stake in Revelation Biosciences, Inc., holding 250,755 shares of common stock.

Summary

• Armistice Capital, LLC and Steven Boyd have jointly reported beneficial ownership of 250,755 shares of common stock in Revelation Biosciences, Inc.
• This represents 9.99% of the company's common stock, par value $0.001 per share.
• The shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital, LLC acting as the investment manager and exercising shared voting and dispositive power over the securities.
• Steven Boyd, as the managing member of Armistice Capital, LLC, is also deemed to beneficially own these securities.
• The acquisition of shares was made in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• The filing was made under Rule 13d-1(c), indicating a passive investment intent.

Sentiment

Score: 7

Explanation: The disclosure of a nearly 10% passive stake by Armistice Capital, LLC, a notable investment firm, in Revelation Biosciences, Inc. is generally perceived as a positive signal by the market, indicating institutional confidence in the company's long-term prospects.

Positives

• A significant institutional investor, Armistice Capital, LLC, has taken a nearly 10% stake in Revelation Biosciences, Inc., potentially signaling confidence in the company's future prospects.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

This Schedule 13G filing indicates a significant passive investment by Armistice Capital, LLC, a hedge fund, in Revelation Biosciences, Inc. Such filings are common when an institutional investor acquires more than 5% of a company's voting shares without intending to influence or change control. For the biotechnology sector, institutional investment can be a crucial signal of market confidence, especially for smaller or development-stage companies like those often found in 'Biosciences' firms, as it can attract further investor interest.

Stakeholder Impact

• Shareholders: May view the significant institutional investment as a positive indicator, potentially leading to increased investor confidence and demand for the stock.
• Company Management: Could see this as validation of their strategy and potentially benefit from increased market liquidity and visibility.

Key Dates

Recommendation

While the disclosure of a significant passive stake by Armistice Capital is a positive signal, a Schedule 13G filing alone does not provide enough fundamental information about Revelation Biosciences, Inc.'s operations, financials, or strategic direction to warrant a 'buy' or 'sell' recommendation. It primarily indicates an institutional investor's position. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current position while awaiting further operational or financial updates from the company.

Keywords

Revelation Biosciences, Armistice Capital, Steven Boyd, beneficial ownership, Schedule 13G, common stock, institutional investment, passive investment, biotech